| Showcasing Integrated Solutions for Clinical and Molecular Diagnostics to Strengthen Global Competitiveness
This year’s LMCE 2025, held under the theme “Inspiration & Innovation,” marked the largest conference to date, featuring around 90 companies and 190 booths. In celebration of their respective milestones — the 40th anniversary of Samkwang Medical Lab and the 10th anniversary of SML Genetree — the two companies hosted special exhibition booths. They showcased their technological achievements and continued innovation in the diagnostic testing field, sharing their group vision and values with visitors.
Samkwang Medical Lab introduced its major diagnostic test portfolio, including:
Non-hereditary blood cancer gene panel test
(1-3)-β-D-Glucan test
Anti-ENA and anti-DNA antibody screening
BRCA1/2 gene mutation test
Alzheimer’s disease risk blood test (AlzOn)
Respiratory virus and pneumonia pathogen screening
Tumor marker tests
MAST Plus 54-type allergy test
SML Genetree presented a wide range of molecular diagnostic products centered on its flagship brand NamuPlex™, including STD12 Real-time PCR Kit and GI Bacteria 1·2·3 Real-time PCR Kits.
Additionally, the company attracted strong attention from field experts by exhibiting a comprehensive molecular diagnostic solution — from DNA/RNA extraction to result analysis — using its GenetreEX™ 96 Extraction System, alongside various test kits such as those for respiratory viruses, bacteria, MTBC/NTM, and HLA-B27/B51 typing.
SML Genetree stated, “Through our integrated solutions that meet diverse clinical needs in the molecular diagnostics field, we aim to enhance diagnostic efficiency and accuracy. We will continue to strengthen our global competitiveness through ongoing research and development.”
Samkwang Medical Lab commented, “Our 40-year journey alongside the advancement of laboratory medicine has been made possible by the trust and collaboration built with our partners in the medical field. We will continue to contribute to public health based on innovation and professionalism, upholding our value of ‘Accurate Testing, Reliable Results.’”
Source: PharmNews (팜뉴스)
https://www.pharmnews.com/news/articleView.html?idxno=264187
| Showcasing Integrated Solutions for Clinical and Molecular Diagnostics to Strengthen Global Competitiveness
This year’s LMCE 2025, held under the theme “Inspiration & Innovation,” marked the largest conference to date, featuring around 90 companies and 190 booths. In celebration of their respective milestones — the 40th anniversary of Samkwang Medical Lab and the 10th anniversary of SML Genetree — the two companies hosted special exhibition booths. They showcased their technological achievements and continued innovation in the diagnostic testing field, sharing their group vision and values with visitors.
Samkwang Medical Lab introduced its major diagnostic test portfolio, including:
Non-hereditary blood cancer gene panel test
(1-3)-β-D-Glucan test
Anti-ENA and anti-DNA antibody screening
BRCA1/2 gene mutation test
Alzheimer’s disease risk blood test (AlzOn)
Respiratory virus and pneumonia pathogen screening
Tumor marker tests
MAST Plus 54-type allergy test
SML Genetree presented a wide range of molecular diagnostic products centered on its flagship brand NamuPlex™, including STD12 Real-time PCR Kit and GI Bacteria 1·2·3 Real-time PCR Kits.
Additionally, the company attracted strong attention from field experts by exhibiting a comprehensive molecular diagnostic solution — from DNA/RNA extraction to result analysis — using its GenetreEX™ 96 Extraction System, alongside various test kits such as those for respiratory viruses, bacteria, MTBC/NTM, and HLA-B27/B51 typing.
SML Genetree stated, “Through our integrated solutions that meet diverse clinical needs in the molecular diagnostics field, we aim to enhance diagnostic efficiency and accuracy. We will continue to strengthen our global competitiveness through ongoing research and development.”
Samkwang Medical Lab commented, “Our 40-year journey alongside the advancement of laboratory medicine has been made possible by the trust and collaboration built with our partners in the medical field. We will continue to contribute to public health based on innovation and professionalism, upholding our value of ‘Accurate Testing, Reliable Results.’”
Source: PharmNews (팜뉴스)
https://www.pharmnews.com/news/articleView.html?idxno=264187